TScan Therapeutics, Inc.
$1.43
▼
-1.94%
2026-04-21 09:45:00
www.tscan.com
NGM: TCRX
Explore TScan Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$67.71 M
Current Price
$1.43
52W High / Low
$2.57 / $0.88
Stock P/E
—
Book Value
$2.16
Dividend Yield
—
ROCE
-64.64%
ROE
-71.28%
Face Value
—
EPS
$-1
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
142
Beta
1.01
Debt / Equity
76.46
Current Ratio
8.41
Quick Ratio
8.41
Forward P/E
-1.37
Price / Sales
5.79
Enterprise Value
$1.48 M
EV / EBITDA
-0.01
EV / Revenue
0.14
Rating
Strong Buy
Target Price
$6
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Larimar Therapeutics, Inc. | $4.81 | — | $499.68 M | — | -212.84% | -1.33% | $6.42 / $1.73 | $0.94 |
| 2. | MacroGenics, Inc. | $3.48 | — | $228.17 M | — | -34.08% | -86.94% | $3.88 / $1.11 | $0.88 |
| 3. | Axsome Therapeutics, Inc. | $184.13 | — | $9.35 B | — | -54.42% | -2.52% | $191.5 / $96.09 | $1.74 |
| 4. | Cabaletta Bio, Inc. | $3.31 | — | $382.95 M | — | -149.87% | -1.27% | $3.78 / $1.06 | $1.11 |
| 5. | FibroBiologics, Inc. | $1.53 | — | $5.37 M | — | -211.82% | -4.19% | $30.6 / $1.03 | $1.85 |
| 6. | Xeris Biopharma Holdings, Inc. | $6.25 | 1,885.02 | $1.04 B | — | 9.09% | -6.96% | $10.08 / $3.95 | $0.08 |
| 7. | Eikon Therapeutics, Inc. | $11.55 | — | $644.25 M | — | -62.8% | -1.25% | $17.4 / $8.58 | $-286.47 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 2.57 M | 2.51 M | 3.08 M | 2.17 M | 0.67 M | — |
| Operating Profit | -23.86 M | -37.05 M | -38.65 M | -36.25 M | -36.71 M | — |
| Net Profit | -22.98 M | -35.71 M | -36.95 M | -34.13 M | -35.81 M | — |
| EPS in Rs | -0.44 | -0.68 | -0.7 | -0.65 | -0.68 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 10.32 M | 2.82 M | 21.05 M | 13.54 M |
| Operating Profit | -135.81 M | -134.82 M | -93.46 M | -66.64 M |
| Net Profit | -129.77 M | -127.5 M | -89.22 M | -66.22 M |
| EPS in Rs | -2.47 | -2.42 | -1.7 | -1.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 228.79 M | 371.12 M | 272.15 M | 199.09 M |
| Total Liabilities | 105.67 M | 130.15 M | 121.28 M | 99.66 M |
| Equity | 123.12 M | 240.97 M | 150.87 M | 99.43 M |
| Current Assets | 157.21 M | 292.72 M | 194.24 M | 124.13 M |
| Current Liabilities | 18.7 M | 35.96 M | 29.82 M | 17.3 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -135.32 M | -110.82 M | -61.36 M | -66.5 M |
| Investing CF | 109.37 M | -52.61 M | -60.76 M | -4.22 M |
| Financing CF | -0.34 M | 208.76 M | 135.44 M | 29.36 M |
| Free CF | -139.73 M | -114.65 M | -64.5 M | -70.73 M |
| Capex | -4.41 M | -3.83 M | -3.15 M | -4.22 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -86.62% | 55.52% | — | — |
| Earnings Growth % | -42.91% | -34.73% | — | — |
| Profit Margin % | -4527.66% | -423.86% | -489.26% | — |
| Operating Margin % | -4787.68% | -444% | -492.32% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -4252.06% | -380.53% | -442.62% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.